New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 22, 2014
12:39 EDTBMY, SNY, ISIS, AVNR, BIIBThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
News For BMY;SNY;ISIS;AVNR;BIIB From The Last 14 Days
Check below for free stories on BMY;SNY;ISIS;AVNR;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 15, 2014
17:09 EDTAVNROn The Fly: Closing Wrap
Stocks on Wall Street were mixed to begin the week, as the Dow managed to register mild gains but the Nasdaq was weighed down by slides in a number of so-called "momentum stocks" like Tesla (TSLA). Investors may remain cautious in the next two sessions ahead of the Fed's much anticipated rate decision and accompanying statement, which is due Wednesday. ECONOMIC EVENTS: In the U.S., New York Fed's Empire state survey for September rose to a five-year high of 27.54. Industrial production unexpectedly dipped 0.1% in August from a downwardly revised 0.2% July gain, missing the forecast for a rise of 0.3%. Capacity utilization dropped to 78.8% last month from 79.1% previously. In China, industrial output increased 6.9% in August versus the same period a year earlier, which was its weakest advance, excluding months that fell during New Year holidays, since December 2008. Chinese retail sales growth for August came in at 11.9%, missing the consensus estimate. COMPANY NEWS: Shares of Apple (AAPL) edged down 3c, or 0.03%, to $101.63 despite the company's announcement that a record 4M iPhone 6 and iPhone 6 Plus pre-orders were placed in the first 24 hours that ordering was available. Demand for the new phones exceeds the initial pre-order supply, the company added, stating that delivery of "many" iPhone pre-orders have been pushed out to October... Microsoft (MSFT) slid 45c, or 0.97%, to $46.24 after the company confirmed an agreement to acquire Mojang, the developer for the "Minecraft" video game franchise, for $2.5B... MAJOR MOVERS: Among the notable gainers was Avanir Pharmaceuticals (AVNR), which surged $5.75, or 85.31%, to $12.49 and was upgraded to Buy from Hold at Jefferies after the company announced results from its phase II clinical trial evaluating the safety and efficacy of its treatment of agitation in patients with Alzheimer's disease. Also higher was SABMiller (SBMRY), which jumped $4.72, or 8.5%, to $60.26 after the Wall Street Journal said that ABInBev (BUD) was looking to obtain financing for an acquisition of the U.K.-based brewer and Heineken (HEINY) confirmed that it rebuffed SABMiller's approach regarding a potential transaction. The news of potential consolidation in the space also drove other beer makers highers, with Molson Coors (TAP) rising $4.20, or 5.85%, to $76.00 and Boston Beer (SAM) gaining 71c, or 0.33%, to $218.47. Among the noteworthy losers was Tesla (TSLA), which dropped $25.34, or 9.08%, to $253.86 after Morgan Stanley analyst Adam Jones wrote that he agrees with the assertion of Tesla's CEO Elon Musk that the company's stock may have gotten ahead of itself. Also lower were shares of NPS Pharmaceuticals (NPSP), which fell $5.42, or 16.56%, to $27.28 after Oppennheimer and Jefferies stated that approval of its Natpara drug for hypoparathyroidism could be delayed after concerns were raised during an FDA panel meeting, even though the advisors were in favor of approving the drug. INDEXES: The Dow rose 43.63, or 0.26%, to 17,031.14, the Nasdaq dropped 48.70, or 1.07%, to 4,518.90, and the S&P 500 declined 1.41, or 0.07%, to 1,984.13.
13:11 EDTAVNRAvanir upgraded to Buy from Hold at Jefferies
12:31 EDTAVNROn The Fly: Midday Wrap
Subscribe for More Information
10:36 EDTAVNRHigh option volume stocks
Subscribe for More Information
10:21 EDTAVNRAvanir price target raised to $12.20 on positive Alzheimer data at Cowen
Subscribe for More Information
09:47 EDTAVNRAvanir price target raised to $17 from $13 at Piper Jaffray
09:35 EDTAVNRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA RSH YHOO GILD TWTR AVNR NFLX BAC C
08:32 EDTAVNRAvanir announces positive Phase II results for AVP-923
Subscribe for More Information
08:01 EDTBIIBAlnylam names Karen Anderson as SVP, Chief Human Resources Officer
Subscribe for More Information
06:13 EDTAVNRStocks with implied volatility top IV index mean; AMD AVNR
Subscribe for More Information
September 12, 2014
10:04 EDTSNYSanofi unit granted orphan status for treatment of Gaucher disease
Subscribe for More Information
07:32 EDTBIIBBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
September 11, 2014
11:29 EDTAVNROptions with increasing implied volatility
Options with increasing implied volatility: VNET AVNR GPRO RAX FTR JDSU PSEC APD SYY GGP
07:31 EDTBIIBBiogen announces 5-year results from TECFIDERA ENDORSE Phase 3 study
Subscribe for More Information
07:31 EDTBIIBBiogen announces new data from Plegridy Phase 3 ADVANCE trial
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY were maintained in people with relapsing forms of multiple sclerosis beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis in Boston. Post-hoc analyses from the two-year, Phase 3 ADVANCE clinical trial confirm that PLEGRIDY’s positive effects on reducing disease activity and disability progression were maintained in year two of the study. A significantly higher proportion of patients taking PLEGRIDY during both years of the study experienced no evidence of disease activity – defined as the absence of clinical and MRI disease activity over two years of treatment – compared to those who switched to PLEGRIDY from placebo. Also, those treated with PLEGRIDY for both years of the study had significant reductions in the risk of 24-week confirmed disability progression compared to patients treated with placebo during the first year. In addition, new data from the second year of ADVANCE show that patients who took PLEGRIDY throughout the study experienced statistically significant improvements in clinical and MRI outcomes – including annualized relapse rate, risk of relapse, risk of 24-week confirmed disability progression, and number of brain lesions – when compared to those who switched to PLEGRIDY after taking placebo for the first year. This new data also showed that the safety profile of PLEGRIDY was consistent between years one and two of the study.
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
September 8, 2014
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information
09:27 EDTBIIBLeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
07:15 EDTBIIBIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use